Who we are

National BioService (NBS) is a fully compliant biospecimens CRO offering professional services in ethical sourcing, processing and characterization of human and primate biospecimens.

Clinical Partners Network

NBS operates a network of over 125 formally contracted and managed clinical Centers in over 30 cities across Russia, covering a wide range of therapeutic areas

Compliance & Traceability

NBS provides its services to customers world-wide in strict compliance with local and international ethical, medical, customs and data protection rules and regulations while demonstrating full traceability of biospecimens to the source

Advanced laboratory capabilities

Six laboratories created and operated by NBS allow for detailed molecular characterization and sophisticated and customizable, yet standardized across NBS laboratories processing of biospecimens, in addition to their extensive clinical annotation


Our partners



LUCARD (Lung Cancer Residual Disease) is a study of minimal residual disease (MRD) in non-small cell lung cancer (NSCLC), investigating the relationship between the level of circulating tumor DNA (ctDNA) after surgery and the risk of cancer recurrence. NGS analysis of ctDNA for the presence of somatic mutations in plasma collected before and after surgery is guided by genetic variants identified in patients’ tumor material. Four leading medical centers in Russia are currently involved in the study.


The oncoBRCA database contains information on the frequencies of variants of BRCA1 / 2 genes established within the framework of the Hereditary Cancer Syndromes Project in Russian. More than 2,000 clinical cases from 35 regions of Russia were analyzed using NGS. The goal of the project is to expand the knowledge about the genetic basis of breast, ovarian, and other cancers by combining information on BRCA1 / 2 variants and relevant clinical data as well as to help in the interpretation of variants distributed in populations of different regions of Russia.


Alzheimer’s disease (AD) biomarkers are being studied in cerebrospinal fluid (CSF) by new multiplexed assay panel for their ability to detect early stages of Alzheimer's disease. The study aims to include assessment of beta-amyloid and tau protein levels in cerebrospinal fluid (CSF) and tears in routing neurological screening of patients for early detection and reliable confirmation of AD diagnosis.

17A Litovskaya str., Saint Petersburg